Replimune skin cancer therapy rejected by FDA

Also: An author shares what happened when her mother refused treatment for her breast cancer

July 22, 2025 Check out STAT+

Sponsored By

Sarah Silbiger/Getty Images STAT+ | Replimune skin cancer therapy rejected by FDA, a sign of regulators' hardened stance The FDA's decision is the latest indication that the agency is taking a hardened stance on drug approvals under regulatory Vinay Prasad. By Adam Feuerstein Opinion: The quick return of medical debt to credit reports is another blow to cancer patients Medical debt isn't accrued irresponsibly; it's accrued out of necessity. Nobody chooses cancer, and nobody chooses medical debt. By Gwen Nichols STAT+ | 10 million expected to lose health insurance under Trump's tax cut law, CBO says Trump's law cuts federal health spending by more than $1 trillion over a decade to help fund tax cuts. By Daniel Payne Adobe Opinion: My mother refused treatment for her breast cancer. Her doctors should have respected her choice Doctors viewed my mother as a waste of time because she refused breast cancer treatment. But she still deserved their care. By Joy Lisi Rankin

More around STAT

---

In case you missed it To prevent ovarian cancers, fallopian tube removal is on the rise HHS to continue funding cancer prevention, tracking work in states after uncertainty Opinion: How farming theory has helped me live beyond my original cancer prognosis

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser